Venus Concept

Venus Concept, Inc. develops, commercializes and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies and related practice enhancement services. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Venus Concept surpasses revenue expectations in Q1 2024 earnings call

Venus Concept's Q1 2024 performance showed resilience with revenue exceeding expectations despite challenges. Strategic initiatives to exit unprofitable markets and focus on cash system sales led to improved financial metrics. The company's progress in key initiatives and financial improvements demonstrate a commitment to long-term growth and stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Venus Concept, Inc. is a global medical technology company, which engages in the business of developing, commercializing, and selling minimally invasive and non-invasive medical aesthetic and hair restoration technologies. It operates under the United States and International geographical segments. The company was founded on November 22, 2002 and is headquartered in Toronto, Canada.

TORONTO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary unaudited revenue results for the three months ended December 31, 2020 and introduced revenue guidance expectations for the twelve months ended December 31, 2021.

Venus Concept Reports Preliminary Revenue Results for Fourth Quarter 2020; Introduces Fiscal Year 2021 Revenue Guidance

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the following upcoming investor conferences in January:

Venus Concept Inc. to Present at Two Upcoming Investor Conferences in January

TORONTO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (Nasdaq: VERO), a global medical aesthetic technology leader, today announced the pricing of its public offering of 11,250,000 shares of its common stock and warrants to purchase 5,625,000 shares of common stock at a combined offering price to the public of $2.00 per share and accompanying warrant. The warrants have an exercise price of $2.50 per share of common stock, are exercisable immediately, and expire five years from the date of issuance. Venus Concept intends to use the gross proceeds of approximately $22.5 million, before deducting underwriting discounts and commissions and estimated offering expenses, from the offering for general corporate purposes, including the funding of research and development activities.

Venus Concept Inc. Announces Pricing of $22.5 Million Public Offering

TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. All of the common stock and warrants to be sold in the proposed offering are to be sold by Venus Concept. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Venus Concept Inc. Announces Proposed Public Offering

New loan and debt exchange agreements significantly enhance balance sheet and financial condition by lowering overall cost of borrowing, reducing annual interest expense and improving future cash flow New loan and debt exchange agreements significantly enhance balance sheet and financial condition by lowering overall cost of borrowing, reducing annual interest expense and improving future cash flow

Venus Concept Announces Debt Refinancing

TORONTO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that the Company will host a virtual “ Aesthetic & Hair Restoration Technology ” event on Thursday, December 10, 2020. The live webcast of the event will begin at 10:00 a.m. ET and conclude at approximately 12:00 p.m. ET.

Venus Concept to Host Virtual “Aesthetic & Hair Restoration Technology” Event on December 10th

Venus Concept, Inc. (VERO) CEO Domenic Serafino on Q3 2020 Results - Earnings Call Transcript

Venus Concept (VERO) delivered earnings and revenue surprises of 25.00% and -21.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q3 Loss, Lags Revenue Estimates

Shares of Venus Concept (NASDAQ:VERO) moved higher by 3.9% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 82.35% over the past year to ($0.18), which beat the estimate of ($0.22).

Recap: Venus Concept Q3 Earnings

TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2020.

Venus Concept Announces Third Quarter and First Nine Months of 2020 Financial Results

TORONTO, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that management will participate in the Stifel 2020 Virtual Healthcare Conference. Management will present on Monday, November 16th at 4:00 p.m. Eastern Time.

Venus Concept Inc. to Present at the Stifel 2020 Virtual Healthcare Conference

TORONTO, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that third quarter of fiscal year 2020 financial results will be released before the market opens on Monday, November 16, 2020.

Venus Concept to Release Third Quarter of Fiscal Year 2020 Financial Results on November 16, 2020

Venus Concept, Inc. (VERO) CEO Domenic Serafino on Q2 2020 Results - Earnings Call Transcript

TORONTO, Aug.  13, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three and six months ended June 30, 2020.

Venus Concept Announces Second Quarter and First Six Months of 2020 Financial Results

TORONTO, July  16, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today reported preliminary revenue results for the three months ended June 30, 2020.

Venus Concept Reports Preliminary Revenue Results for Second Quarter 2020

Venus Viva MD is a new skin rejuvenation solution with differentiated features that allow clinicians in the traditional medical aesthetics community to treat a wider range of skin conditions Venus Viva MD is a new skin rejuvenation solution with differentiated features that allow clinicians in the traditional medical aesthetics community to treat a wider range of skin conditions

Venus Concept Inc. Announces FDA 510(k) Clearance for Venus Viva MD

TORONTO, June  26, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced today that the Company has been added to the Russell 2000®, Russell 3000® and Russell Microcap® Indexes. The Company’s inclusion in these indexes will become effective today after the US market close.

Venus Concept Inc. Joins Russell 2000®, Russell 3000® and Russell Microcap® Indexes

Jaguar Health

Synchronoss

Scorpio Tankers

Forget undervalued stocks, play these top-ranked stocks with rising P/E.

Bet on 4 Stocks With Rising P/E to Beat Market Blues

TORONTO, June  16, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it has entered into a common stock purchase agreement for up to $31 million with Lincoln Park Capital Fund, LLC (“Lincoln Park”), a Chicago-based institutional investor. Upon execution of the purchase agreement, Lincoln Park made an initial purchase of $1.0 million of common stock.

Venus Concept Inc. Announces Common Stock Purchase Agreement for up to $31 Million with Lincoln Park Capital Fund, LLC

Venus Epileve is a new, cost-effective, laser hair removal solution designed for customers in the aesthetics market Venus Epileve is a new, cost-effective, laser hair removal solution designed for customers in the aesthetics market

Venus Concept Inc. Announces FDA 510(k) Clearance for Venus Epileve

Venus Concept Inc. (VERO) CEO Domenic Serafino on Q2 2020 Results - Earnings Call Transcript

Venus Concept (VERO) delivered earnings and revenue surprises of -14.12% and -13.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Venus Concept (VERO) Reports Q1 Loss, Lags Revenue Estimates

TORONTO, May  14, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2020. The Company notes that the financial results provided for the three months ended March 31, 2020 give effect to the merger that closed on November 7, 2019 as described below.

Venus Concept Announces First Quarter of 2020 Financial Results

Venus Concept Inc. (VERO) CEO Domenic Serafino on Q4 2019 Results - Earnings Call Transcript

TORONTO, March  18, 2020  (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced that it entered into a definitive agreement for the sale of shares of its common stock, Series A convertible preferred stock and warrants to purchase common stock in a private placement to a group of investors, including EW Healthcare Partners, HealthQuest Capital and SEDCO Capital. The private placement is expected to result in gross proceeds to the Company of approximately $22.25 million, before deducting placement agent fees and other offering expenses.

News for Venus Concept Stock (VERO)